431 related articles for article (PubMed ID: 24333488)
1. Peritoneal dialysis and inflammation.
Velloso MS; Otoni A; de Paula Sabino A; de Castro WV; Pinto SW; Marinho MA; Rios DR
Clin Chim Acta; 2014 Mar; 430():109-14. PubMed ID: 24333488
[TBL] [Abstract][Full Text] [Related]
2. Biocompatible dialysis fluids for peritoneal dialysis.
Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
[TBL] [Abstract][Full Text] [Related]
3. Effect of neutral pH and low-glucose degradation product-containing peritoneal dialysis solution on residual renal function in peritoneal dialysis patients: a meta-analysis.
Wang J; Zhu N; Yuan W
Nephron; 2015; 129(3):155-63. PubMed ID: 25765060
[TBL] [Abstract][Full Text] [Related]
4. Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis.
Higuchi C; Nishimura H; Sanaka T
Ther Apher Dial; 2006 Aug; 10(4):372-9. PubMed ID: 16911191
[TBL] [Abstract][Full Text] [Related]
5. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions.
Parikova A; Zweers MM; Struijk DG; Krediet RT
Adv Perit Dial; 2003; 19():186-90. PubMed ID: 14763059
[TBL] [Abstract][Full Text] [Related]
6. Inflammation, neoangiogenesis and fibrosis in peritoneal dialysis.
de Lima SM; Otoni A; Sabino Ade P; Dusse LM; Gomes KB; Pinto SW; Marinho MA; Rios DR
Clin Chim Acta; 2013 Jun; 421():46-50. PubMed ID: 23466603
[TBL] [Abstract][Full Text] [Related]
7. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
[TBL] [Abstract][Full Text] [Related]
8. Effect of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions on Residual Renal Function, Urine Volume, and Ultrafiltration: A Systematic Review and Meta-Analysis.
Yohanna S; Alkatheeri AM; Brimble SK; McCormick B; Iansavitchous A; Blake PG; Jain AK
Clin J Am Soc Nephrol; 2015 Aug; 10(8):1380-8. PubMed ID: 26048890
[TBL] [Abstract][Full Text] [Related]
9. Effects of neutral pH and reduced glucose degradation products in a new peritoneal dialysis solution on morphology of peritoneal membrane in rats.
Ikehara O; Nishimura H; Naito T; Higuchi C; Sanaka T
Nephron Exp Nephrol; 2005; 100(1):e30-9. PubMed ID: 15731567
[TBL] [Abstract][Full Text] [Related]
10. Use of new peritoneal dialysis solutions in children.
Canepa A; Verrina E; Perfumo F
Kidney Int Suppl; 2008 Apr; (108):S137-44. PubMed ID: 18379537
[TBL] [Abstract][Full Text] [Related]
11. The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients.
Cho Y; Johnson DW; Badve SV; Craig JC; Strippoli GF; Wiggins KJ
Kidney Int; 2013 Nov; 84(5):969-79. PubMed ID: 23698236
[TBL] [Abstract][Full Text] [Related]
12. Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2006; 22():24-8. PubMed ID: 16983933
[TBL] [Abstract][Full Text] [Related]
13. Acute effects of peritoneal dialysis solutions in the mesenteric microcirculation.
Frajewicki V; Brod V; Kushnir D; Kohan R; Bitterman H
Transl Res; 2009 May; 153(5):249-56. PubMed ID: 19375686
[TBL] [Abstract][Full Text] [Related]
14. Biocompatible peritoneal dialysis solutions: do we have one?
Chaudhary K; Khanna R
Clin J Am Soc Nephrol; 2010 Apr; 5(4):723-32. PubMed ID: 20093342
[TBL] [Abstract][Full Text] [Related]
15. The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?
Perl J; Nessim SJ; Bargman JM
Kidney Int; 2011 Apr; 79(8):814-24. PubMed ID: 21248712
[TBL] [Abstract][Full Text] [Related]
16. Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis.
De Los Ríos T; Pérez-Martínez J; Portoles J; Lichodziejewska-Niemierko M; Rivera M; Nowicki M; Książek A; Tato AM; Bohnhorst C; Feriani M
Perit Dial Int; 2016 9-10; 36(5):569-72. PubMed ID: 27659931
[TBL] [Abstract][Full Text] [Related]
17. Biocompatibility of new peritoneal dialysis solutions: clinical experience.
Garcia-Lopez E; Lindholm B; Tranaeus A
Perit Dial Int; 2000; 20 Suppl 5():S48-56. PubMed ID: 11229612
[TBL] [Abstract][Full Text] [Related]
18. Glucose-based peritoneal dialysis fluids downregulate toll-like receptors and trigger hyporesponsiveness to pathogen-associated molecular patterns in human peritoneal mesothelial cells.
Wu J; Yang X; Zhang YF; Wang YN; Liu M; Dong XQ; Fan JJ; Yu XQ
Clin Vaccine Immunol; 2010 May; 17(5):757-63. PubMed ID: 20200188
[TBL] [Abstract][Full Text] [Related]
19. The impact of relapsing sterile icodextrin-associated peritonitis on peritoneal dialysis outcome.
Basile C; De Padova F; Montanaro A; Giordano R
J Nephrol; 2003; 16(3):384-6. PubMed ID: 12832738
[TBL] [Abstract][Full Text] [Related]
20. Neutral pH and low-glucose degradation product dialysis fluids induce major early alterations of the peritoneal membrane in children on peritoneal dialysis.
Schaefer B; Bartosova M; Macher-Goeppinger S; Sallay P; Vörös P; Ranchin B; Vondrak K; Ariceta G; Zaloszyc A; Bayazit AK; Querfeld U; Cerkauskiene R; Testa S; Taylan C; VandeWalle J; Yap Y; Krmar RT; Büscher R; Mühlig AK; Drozdz D; Caliskan S; Lasitschka F; Fathallah-Shaykh S; Verrina E; Klaus G; Arbeiter K; Bhayadia R; Melk A; Romero P; Warady BA; Schaefer F; Ujszaszi A; Schmitt CP
Kidney Int; 2018 Aug; 94(2):419-429. PubMed ID: 29776755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
